Kolistin Zentiva (Colistimethate Sodium)

Kolistin Zentiva (colistimethate sodium) is employed for infections caused by Gram‑negative bacteria, particularly when administered via the intrathecal route.

• Ventilator‑associated pneumonia: helps eradicate multidrug‑resistant Pseudomonas aeruginosa in the lungs.
• Complicated urinary tract infection: targets resistant Gram‑negative organisms causing renal or bladder infection.
• Bacteremia/septicemia: provides systemic control of Gram‑negative sepsis when other agents are ineffective.
• Meningitis: delivers colistin directly to cerebrospinal fluid to treat Gram‑negative meningitis.

• Colistimethate sodium is a cationic lipopeptide that binds to the lipid A component of lipopolysaccharide in the outer membrane of Gram‑negative bacteria. This interaction displaces calcium and magnesium ions, disrupting membrane integrity, increasing permeability, and causing leakage of intracellular contents, ultimately leading to bacterial cell death. The drug does not readily cross the mammalian cell membrane, which limits toxicity to host tissues at therapeutic concentrations. Its bactericidal activity is rapid and concentration‑dependent.

Colistimethate sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nephrotoxicity: elevated serum creatinine and reduced renal function.
• Neurotoxicity: tingling, numbness, dizziness, or headache.
• Gastrointestinal upset: nausea, vomiting, or abdominal pain.
• Skin reactions: rash or pruritus.

Serious or Rare Side Effects

• Acute renal failure: rapid loss of kidney function requiring dialysis.
• Neuromuscular blockade: muscle weakness leading to respiratory failure.
• Seizures: convulsive episodes, especially in patients with renal impairment.
• Anaphylaxis: severe allergic reaction with hypotension and airway compromise.

When using Kolistin Zentiva, several precautions should be observed to minimize risk and ensure safe therapy.

• Renal function monitoring: assess serum creatinine and glomerular filtration rate before and during treatment.
• Neurotoxicity surveillance: watch for paresthesia, dizziness, or altered mental status.
• Dosage adjustment in renal impairment: reduce dose according to estimated creatinine clearance.
• Avoid concurrent nephrotoxic agents: limit use with aminoglycosides, vancomycin, or loop diuretics.
• Pregnancy and lactation: prescribe only if potential benefits outweigh potential risks to the fetus or infant.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Colistimethate sodium can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid)

• Aminoglycosides: additive nephrotoxicity may lead to acute kidney injury.
• Loop diuretics (e.g., furosemide): increased risk of renal toxicity.
• Neuromuscular blocking agents: heightened risk of respiratory paralysis.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate renal impairment.
• Vancomycin: potential additive nephrotoxic effect requiring renal function monitoring.
• Contrast media used in imaging: monitor kidney function before and after administration.